Deep Inquiry🧬 Biology & pharmacology

BPC-157: what the evidence actually supports

β€œDoes BPC-157 act as a transcription factor interacting directly with the nucleus to upregulate VEGF mRNA, or does it rely on a classical membrane receptor cascade?”

The short answer

I find no evidence that BPC-157 itself is a sequence-specific transcription factor; altered growth-factor expression does not establish direct nuclear action. The best-known endothelial study reported increased VEGFR2, not VEGF-A, expression and receptor internalization associated with Akt–eNOS signaling, without identifying a BPC-157-binding membrane receptor.[1] However, the question's two alternatives are incomplete: a 2026 study reports an intracellular interaction with FBXO22, stabilizing the endogenous transcription factor BACH1, so β€œno binding target has been reported” is now too strong.[6] These are preclinical mechanistic observations, not established human therapeutic effects, and the small human reports do not settle safety or efficacy.[9,10,11] My confidence is high in rejecting the claimed evidence for direct transcription-factor activity, but only medium in a unified positive mechanism.

First correct the question, then evaluate the mechanism

The BIOL101 extracted notes describe BPC-157 as β€œknown to trigger angiogenesis” and ask whether it bypasses the membrane to upregulate VEGF mRNA. The fuller picture is that particular experimental systems show angiogenic readouts, while the initiating interaction and the generality of the response remain unsettled. I should not turn a course-level mechanistic question into an established clinical premise. Nor should I collapse VEGF-A, a ligand, and VEGFR2, a receptor, into the same molecular measurement.[1,4]

Hsieh and colleagues used endothelial cultures, chick chorioallantoic membranes, and a rat hind-limb ischemia model. Their abstract explicitly reports increased VEGFR2 mRNA and protein, but not VEGF-A, in cultured endothelial cells.[1] Huang and colleagues, working with rat alkali burns and endothelial cultures, did report VEGF-related increases.[4] The difference could reflect experimental context rather than contradiction, but it rules out the simple statement that every angiogenic BPC-157 result is explained by increased VEGF transcription.

The sequence is GEPPPGKPADDAGLV, explicitly given in the PL 14736 wound-healing paper: fifteen residues, with four prolines, one lysine, and three acidic side chains.[5] My sequence-based inference is that this short, acidic, proline-rich peptide is not a plausible conventional autonomous DNA-binding transcription factor. It has no demonstrated DNA-binding domain, no demonstrated transcriptional activation domain, and no recognizable classical basic nuclear localization signal. Those observations lower plausibility; they are not a mathematical proof that short peptides cannot interact with nuclear proteins.

The missing localization signal is particularly easy to overstate. At roughly 1.4 kDa, an intact peptide already present in the cytosol would not necessarily need an importin-mediated nuclear import mechanism; crossing the plasma membrane and escaping endosomes are separate questions. Unclear membrane permeability is not evidence of impossibility, and a reported intracellular interaction deserves evaluation rather than dismissal based on size. Conversely, nuclear fluorescence would establish neither intact peptide identity nor sequence-specific DNA binding.

Steady-state mRNA abundance is a balance between synthesis and degradation. In the elementary model, dM/dt = s βˆ’ kM, and at steady state M = s/k. A hypothetical twofold increase can result either from doubling transcription rate s or halving degradation constant k; neither observation says where the initiating molecule binds. Increased transcript abundance alone therefore cannot distinguish a membrane cascade, an intracellular protein interaction, altered RNA stability, or direct transcriptional action.

What each proposed pathway actually demonstrates

I separate a biochemical response, pathway dependence, and direct molecular engagement. These are different evidentiary levels: a phosphoprotein change is not a binding assay, and blocking a required downstream component does not prove it is the primary receptor. The following mechanisms come from different systems; I do not assume that they form one experimentally demonstrated chain.

  1. VEGFR2 activation and internalization. Hsieh et al. observed increased receptor expression and internalization, with time-dependent VEGFR2–Akt–eNOS pathway activation. Dynasore, an endocytosis inhibitor, suppressed internalization, signaling, and enhanced endothelial tube formation.[1] This supports an endocytosis-associated mechanism in that system, but dynasore is not a receptor-specific binding probe. The study does not establish that BPC-157 occupies VEGFR2's ligand-binding site, and receptor transactivation or altered trafficking remain alternatives.

  2. FAK–paxillin and cytoskeletal remodeling. Chang et al. found increased migration, spreading, F-actin formation, and stress survival in rat tendon fibroblasts, with increased phosphorylation of focal adhesion kinase and paxillin but unchanged total protein amounts.[2] Importantly, BPC-157 did not directly increase proliferation in their cultured fibroblast assay. That distinction matters: improved explant outgrowth can reflect migration and survival rather than faster cell division. These findings locate responsive machinery but do not identify the initial peptide-binding partner.

  3. Growth hormone receptor abundance. A separate rat tendon-fibroblast study reported dose- and time-dependent increases in growth hormone receptor mRNA and protein. Adding growth hormone to BPC-157-pretreated cells enhanced proliferation-related readouts and JAK2 activation.[3] The evidence concerns sensitization to another ligand, not proof that BPC-157 itself is a growth hormone receptor agonist. Receptor upregulation is a downstream expression phenotype unless direct engagement is independently shown.

  4. ERK1/2 and immediate-response genes. The alkali-burn study linked tissue repair and endothelial responses to ERK1/2 phosphorylation and downstream c-Fos, c-Jun, and Egr-1 changes.[4] The earlier PL 14736 study measured induction of egr-1 and its repressor nab2 in Caco-2 cells alongside wound-healing observations in rodents.[5] EGR-1 is an endogenous transcription factor; inducing its expression does not make the administered peptide a transcription factor. NAB2 induction also suggests feedback rather than an indefinitely increasing repair switch.

  5. Nitric oxide signaling. The VEGFR2 study implicates endothelial nitric oxide synthase downstream of Akt.[1] A 2026 study adds human tissue evidence: isolated internal mammary artery rings from twelve surgical donors relaxed in response to BPC-157, with stronger responses in intact endothelium and attenuation by the NOS inhibitor L-NAME.[12] That is ex vivo pharmacology, not a human treatment trial, and residual responses indicate that NO is not necessarily the whole explanation. Neither vascular relaxation nor eNOS activation demonstrates safe systemic angiogenesis.

  6. The new intracellular candidate. Zhang et al.'s 2026 abstract reports that intracellular BPC157 engages the E3 ubiquitin-ligase adaptor FBXO22 through its third-position proline, suppressing BACH1 ubiquitination and degradation and increasing endothelial proliferation and tube formation.[6] This directly changes the audit: there is now a published candidate binding partner, although not an established classical cell-surface receptor. I verified the paper and read its abstract, not its complete experimental record, so I do not treat binding affinity, cellular uptake, specificity, or independent replication as settled. Stabilizing an existing transcription factor is conceptually different from being one.

β”Œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”
β”‚ BPC-157 EXPOSURE      β”‚
β””β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”¬β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”˜
           β”‚ INITIATING STEPS NOT UNIFIED
     β”Œβ”€β”€β”€β”€β”€β”΄β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”
     ↓                                ↓
β”Œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”   β”Œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”
β”‚ MEMBRANE / TRAFFICKINGβ”‚   β”‚ INTRACELLULAR FBXO22      β”‚
β”‚ VEGFR2 ASSOCIATION   β”‚   β”‚ INTERACTION REPORTED 2026 β”‚
β””β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”¬β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”˜   β””β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”¬β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”˜
           ↓                             ↓
β”Œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”   β”Œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”
β”‚ AKT–ENOS; FAK; ERK   β”‚   β”‚ BACH1 STABILIZATION       β”‚
β”‚ DISTINCT MODEL DATA  β”‚   β”‚ ENDOGENOUS TF             β”‚
β””β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”¬β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”˜   β””β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”¬β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”˜
           β””β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”¬β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”˜
                          ↓
             β”Œβ”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”
             β”‚ CELLULAR RESPONSE /        β”‚
             β”‚ GENE-EXPRESSION CHANGES    β”‚
             β””β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”€β”˜
NO DEMONSTRATED ARROW: BPC-157 β†’ SEQUENCE-SPECIFIC DNA BINDING

The diagram is an evidence map, not a verified wiring diagram. Its left branch groups observations from different papers; its right branch preserves the newer candidate without claiming it explains every older phenotype.[1,2,4,6] The honest conclusion is therefore neither β€œdefinitely a classical receptor cascade” nor β€œdefinitely nuclear.” A unified mechanism must explain both early signaling and later transcriptional responses with identifiable, reproducible intermediate steps.

Stability is not exposure: the pharmacokinetic check

The frequently repeated gastric-juice stability claim comes through a literature that describes BPC-157 as a stable fragment related to a gastric protective compound. The Zagreb review states resistance in human gastric juice for more than a day.[8] I read that as the review's claim, not an independently reproduced lot-specific stability specification. Gastric acid resistance, protease resistance, epithelial transport, plasma persistence, and shelf stability are different properties measured in different matrices.

He et al. measured parent-peptide pharmacokinetics in rats and beagle dogs and reported elimination half-lives below thirty minutes, with metabolism into smaller peptides and amino acids.[7] Their measured systemic availability also differed between species under the studied experimental route. Those results do not contradict stability in gastric juice: a molecule can resist one matrix yet be rapidly cleared or metabolized in another. They do undermine the shortcut from β€œstable gastric peptide” to β€œdurable intact systemic exposure.”

A calculated illustration makes the distinction concrete. If an ideal one-compartment parent compound had a thirty-minute half-life, after two hours the remaining fraction would be 2^βˆ’4 = 6.25%; a shorter half-life would leave less under those assumptions. This is not a human prediction, an administration recommendation, or a reconstruction of the paper's full model. Likewise, tissue radioactivity from a labeled peptide can represent metabolites rather than intact active parent, so a distribution signal cannot automatically establish target-site exposure.[7]

Evidence breadth is not independent replication

For a reproducible snapshot through October 1, 2026, I queried PubMed for BPC157, BPC-157, β€œBPC 157,” PL14736, or β€œPL 14736” in All Fields, restricted by publication date to 1900/01/01–2026/10/01. This returned 233 records; adding Sikiric P[Author] returned 175, or 75.1%.[17] These are search-result counts, including reviews and mixed-scope papers, not 233 independent experiments. They are also not an exact institutional census: author presence is a transparent proxy for concentration around Predrag Sikiric's Zagreb research network, not a claim that every coauthor works there.

That concentration is a reason to demand external replication, not evidence of misconduct or automatic invalidity. The tendon, endothelial, pharmacokinetic, and newer intracellular studies provide work beyond a single group, but different positive phenotypes are not necessarily replications of the same mechanism.[1,2,3,6,7] The literature reviewed here remains overwhelmingly rodent, other animal, and cell-culture work. I have not calculated a systematic species-by-species denominator, so I do not present an invented percentage of animal studies.

Human evidence: small reports, tissue experiments, and registrations

I distinguish human administration studies, experiments on excised human tissue, and trial registrations. A registry entry describes a planned or reported study; it is not an efficacy result. Searching the date-bounded PubMed corpus and the ClinicalTrials.gov v2 API identified the following evidence, rather than the outdated blanket statement β€œthere are no human studies.”[9,10,11,12,13]

  • Knee pain, 2021: a retrospective series included seventeen patients, sixteen contacted for follow-up. Twelve received BPC-157 alone and four received a combination with thymosin-beta-4; eleven of twelve in the BPC-only group reported improvement. The abstract says no specific instruments measured function, quality of life, stiffness, or daily activities.[9] Recall, selection, expectation, mixed diagnoses, and combination treatment prevent this from demonstrating structural tendon or cartilage repair.
  • Interstitial cystitis, 2024: an uncontrolled pilot included twelve women and reported substantial symptom improvement, with no reported adverse events.[10] Without a comparison group and blinded assessment, the report cannot separate treatment effects from procedural effects, natural fluctuation, or reporting bias. Its small size also cannot characterize uncommon harms.
  • Intravenous safety pilot, 2025: two adults, both previously exposed to BPC-157, underwent short-term monitoring with no reported adverse effects or measured biomarker changes.[11] Prior exposure limits representativeness, and two participants cannot establish general safety. As a deliberately simplified calculation, even if an adverse event had a true independent probability of 10% per participant, two participants would both avoid it with probability 0.9Β² = 81%.
  • Human artery rings, 2026: the twelve-donor study supplies functional NO-related evidence in excised vessels, not outcomes after administering BPC-157 to patients.[12] Human tissue is translationally informative without being clinical efficacy evidence.

The API query query.term=BPC-157, retrieved for this audit, returned four registrations, all with hasResults=false.[13] NCT02637284 is the older phase 1 PCO-02 safety/pharmacokinetics trial, with estimated enrollment of 42 and status UNKNOWN. NCT07437547 is a phase 2 hamstring-strain trial, registered in February 2026, listed RECRUITING with estimated enrollment of 120. These statuses are registry statements, not independent confirmation of recruitment or conduct.

NCT07803250 is a phase 1 rotator-cuff-repair trial first posted September 3, 2026, listed NOT_YET_RECRUITING, with estimated enrollment of 30 and an estimated 2027 start. NCT07752381 is a single-group, open-label peptide-gummy study, listed COMPLETED with actual enrollment of 40, completed in November 2025 but first posted in August 2026.[13] I mention that formulation only to inventory the registry, not to propose a product or route. Late registration and absence of posted results limit what can be checked prospectively.

Older reviews also refer to ulcerative-colitis and other human development programs.[8] I could not verify a complete primary clinical report for those programs in this audit and therefore do not turn those references into additional demonstrated successes, claim a reliable pooled participant count, or reproduce unverified efficacy numbers. FDA's 2026 meeting materials confirm that ulcerative colitis was the use evaluated for BPC-157-related substances; an advisory review is not itself clinical evidence.[15] I found no published confirmatory randomized efficacy result in the searches performed, but this targeted audit is not a systematic review of every registry worldwide.

Experiments that would discriminate mechanisms

My proposed research program starts with causal discrimination, not another broad wound-healing endpoint. I would prespecify one cellular model, an early signaling outcome, a later expression outcome, and a reproducible material specification. A dose–response relationship should be measured alongside viability and actual peptide recovery from the assay matrix. Otherwise apparent mechanism can be adsorption, degradation, impurities, or nonspecific cell stress.

  1. Test receptor dependence without confusing it with binding. Knock down VEGFR2, restore it with a knockdown-resistant construct, and compare receptor-blocking antibodies and kinase inhibition with matched controls. Loss of effect supports dependence; saturable binding and competition with intact peptide are needed to claim a receptor interaction. Endocytosis blockade alone remains too broad to identify a receptor.
  2. Test, rather than assume, a GPCR branch. Pertussis toxin can probe Gi/o-sensitive signaling with a positive-control pathway and cell-viability checks. A negative result does not exclude all GPCRs, and a positive result can reflect an indirect pathway. It is not a universal membrane-receptor detector.
  3. Track intact peptide and intracellular engagement. Use labeled-peptide localization with extracellular quenching, endosomal markers, and cytosolic/nuclear fractionation controls. Confirm intact peptide by LC–MS rather than trusting the label, and show that labeling preserves activity. Test FBXO22 depletion and rescue, BACH1 abundance and turnover, and a chemically matched third-position substitution to challenge the newly reported mechanism.[6]
  4. Separate transcription from RNA persistence. Combine early phosphoprotein measurements, nascent-RNA measurements, and an actinomycin D time course to estimate transcript decay. Actinomycin D is globally disruptive, so its effect alone cannot locate peptide action. A promoter-reporter response also remains indirect unless sequence-specific peptide–DNA engagement is independently demonstrated.
  5. Make specificity and replication hard to evade. Include several scrambled-sequence controls with identical composition, matrix blanks, independently synthesized lots, and impurity-matched controls. Scrambling can change solubility or proteolysis, so negative scrambled controls are informative only after exposure is checked. Replicate the prespecified effect in an independent laboratory before treating it as a product property.

Regulatory status is a dated observation, not a slogan

The historical starting point is FDA's 2023 placement of BPC-157 in the 503A Category 2 safety-risk framework. The current FDA page, checked for this October 2026 audit and marked current April 22, 2026, places BPC-157 under β€œBulk drug substances nominated but withdrawn,” not the active Category 2 table.[14] It retains warnings about potential immunogenicity, peptide-related impurities, API-characterization complexity, and absent or limited safety information. I therefore should not label its current table position simply β€œCategory 2,” nor interpret nomination withdrawal as FDA approval or proof of safety.

FDA also held a July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting addressing BPC-157-related substances for ulcerative colitis. The agency page explicitly says committee recommendations are non-binding.[15] I verified the meeting page but could not retrieve the linked BPC briefing PDF; I do not assert its detailed conclusions or an exact committee vote. None of the agency material verified here establishes an approved BPC-157 therapeutic product or supplies PP with authorization for clinical claims.

WADA's 2026 Prohibited List includes BPC-157 in S0, Non-Approved Substances, prohibited at all times under the anti-doping framework.[16] This is a sports-governance classification, not a substitute for a pharmacologic risk assessment or a blanket prohibition on laboratory research. FDA compounding policy and WADA eligibility rules answer different questions. Neither should be compressed into the marketing claim β€œsafe but banned.”

What this means for Peptide Partners

For PP, the useful deliverable is a defensible analytical identity and content specification, not a therapeutic narrative. Larissa's laboratory should define the sequence, terminal chemistry, counterion, water content, and reporting basis before comparing lots. β€œBPC-157 acetate” does not by itself specify how much acetate, water, or peptide a weighed sample contains. The FDA's impurity and characterization concerns reinforce why a generic percentage-purity badge is insufficient.[14]

For the unmodified sequence with free amino and carboxyl termini, my calculated neutral monoisotopic mass is approximately 1418.7042 Da; the calculated singly protonated ion is approximately 1419.7114 m/z. These are theoretical identity checks, not measurements of PP inventory. Intact high-resolution mass should be paired with sequence-informative tandem MS, because isomers and some sequence errors can share nominal or exact mass. A terminal modification requires a different theoretical target.

I would ask suppliers for raw chromatograms, integration rules, mass spectra, batch traceability, synthesis/purification descriptions, and counterion and water measurements. RP-HPLC area purity is detector- and method-dependent and is not automatically peptide mass fraction, concentration, biological potency, or sterility. An orthogonal separation and targeted impurity investigation should challenge deletion sequences, truncations, epimers, and coeluting species rather than assuming a single clean peak resolves them. Endotoxin or microbial controls should be chosen for the intended research system; cell assays can be confounded even without any human-use context.

A hypothetical content calculation illustrates the reporting problem: a 10.0 mg research sample containing 8% water and 7% counterion/other nonpeptide mass contains at most 8.5 mg peptide-related material before sequence-related impurities are accounted for. Multiplying by an HPLC area percentage is not justified without comparable response factors and an appropriate assay model. A quantitative content method calibrated with a characterized reference is needed to make a mass claim. The CoA should distinguish measured values, calculated identity, method limits, and untested attributes.

For stability, I would request stability-indicating LC–MS/HPLC data under defined research storage and matrix conditions, with time-zero recovery, container adsorption, and degradation mass balance. The gastric-juice literature does not establish PP shelf life.[7,8] If a biological assay is developed, its certificate should report only that specified research assay and its reproducibility, not claim β€œheals tendons,” β€œregenerates cartilage,” β€œclinically safe,” or β€œproven VEGF transcription factor.” Research-use-only labeling is a boundary on intended use, not a scientific or regulatory exemption for unsupported therapeutic promotion.

Questions to bring to the lab

  1. Which orthogonal measurements will distinguish correct sequence and terminal chemistry from a merely correct intact mass?
  2. Can we report peptide content separately from HPLC area purity, water, counterion, and residual solvents, with a traceable uncertainty budget?
  3. Which synthesis-related impurities could coelute in our current method, and which representative challenge materials should we obtain?
  4. How much intact peptide reaches the cells in a proposed signaling assay after adsorption and degradation are measured?
  5. Can an independent laboratory reproduce a prespecified VEGFR2 or FBXO22/BACH1 readout using blinded, independently synthesized lots?
  6. What minimal experiments would distinguish membrane dependence from intracellular engagement without relying on fluorescent-label artifacts?
  7. Which exact claims belong on the CoA, which belong only in a qualified literature note, and which should never appear in PP's research-product descriptions?

What I still don't know

I do not know whether the reported FBXO22 interaction explains the earlier endothelial findings, whether multiple initiating mechanisms coexist, or which metabolites retain activity. I have not reviewed the complete 2026 binding study's methods or independently reproduced any of these experiments. A membrane receptor remains unidentified in the evidence assessed here; a candidate intracellular partner is now reported, so the older blanket β€œno target” claim needs revision.[1,6]

Human exposure–response relationships, uncommon adverse effects, durable outcomes, and independent replication remain major gaps. A short preclinical half-life neither rules out lasting downstream effects nor establishes useful clinical exposure.[7] The defensible synthesis is narrower than enthusiasm or dismissal: BPC-157 has experimentally interesting effects, but the transcription-factor claim is unsupported, a single classical membrane cascade is unproven, and analytical confidence must not be sold as clinical confidence.

References

  1. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. doi:10.1007/s00109-016-1488-y
  2. Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011;110(3):774-80. doi:10.1152/japplphysiol.00945.2010
  3. Chang CH, Tsai WC, Hsu YH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-77. doi:10.3390/molecules191119066
  4. Huang T, Zhang K, Sun L, et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Des Devel Ther. 2015;9:2485-99. doi:10.2147/DDDT.S82030
  5. Tkalcević VI, Cuzić S, Brajsa K, et al. Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. Eur J Pharmacol. 2007;570(1-3):212-21. doi:10.1016/j.ejphar.2007.05.072
  6. Zhang J, Liu M, Ou H, et al. BPC157 drives angiogenesis through FBXO22-dependent stabilization of BACH1. Cell Commun Signal. 2026;24(1). doi:10.1186/s12964-026-02694-6
  7. He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. doi:10.3389/fphar.2022.1026182
  8. Seiwerth S, Milavic M, Vukojevic J, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Front Pharmacol. 2021;12:627533. doi:10.3389/fphar.2021.627533
  9. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PMID:34324435
  10. Lee E, Walker C, Ayadi B. Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Altern Ther Health Med. 2024;30(10):12-17. PMID:39325560
  11. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24. PMID:40131143
  12. Yildirim AK, Dastan AO, Demeli Ertus M, et al. Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery. J Clin Med. 2026;15(9). doi:10.3390/jcm15093488
  13. National Library of Medicine. ClinicalTrials.gov API v2: BPC-157 study search. Registry snapshot accessed October 1, 2026. https://clinicaltrials.gov/api/v2/studies?query.term=BPC-157
  14. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Page current April 22, 2026; accessed October 1, 2026. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  15. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Accessed October 1, 2026. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
  16. World Anti-Doping Agency. International Standard Prohibited List: The 2026 Prohibited List. Effective January 1, 2026. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
  17. National Library of Medicine. PubMed: date-bounded BPC-157/PL14736 corpus and Sikiric P author subset. E-utilities search and summary snapshot, October 1, 2026. https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esearch.fcgi?db=pubmed&retmode=json